W.G. Shaheen & Associates DBA Whitney & Co Has $7.89 Million Stake in Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

W.G. Shaheen & Associates DBA Whitney & Co lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 0.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,040 shares of the company’s stock after acquiring an additional 205 shares during the quarter. Merck & Co., Inc. makes up approximately 1.8% of W.G. Shaheen & Associates DBA Whitney & Co’s portfolio, making the stock its 18th biggest position. W.G. Shaheen & Associates DBA Whitney & Co’s holdings in Merck & Co., Inc. were worth $7,885,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRK. Norges Bank acquired a new position in Merck & Co., Inc. during the 4th quarter worth about $2,166,688,000. BlackRock Inc. lifted its holdings in Merck & Co., Inc. by 5.6% during the 4th quarter. BlackRock Inc. now owns 194,589,541 shares of the company’s stock worth $14,868,587,000 after buying an additional 10,315,510 shares during the period. FMR LLC lifted its holdings in Merck & Co., Inc. by 41.2% during the 1st quarter. FMR LLC now owns 11,111,444 shares of the company’s stock worth $924,139,000 after buying an additional 3,244,078 shares during the period. Geode Capital Management LLC lifted its holdings in Merck & Co., Inc. by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 34,032,366 shares of the company’s stock worth $2,596,161,000 after buying an additional 3,219,877 shares during the period. Finally, APG Asset Management N.V. lifted its holdings in Merck & Co., Inc. by 326.2% during the 4th quarter. APG Asset Management N.V. now owns 3,792,515 shares of the company’s stock worth $253,498,000 after buying an additional 2,902,600 shares during the period. 76.05% of the stock is currently owned by institutional investors.

In related news, EVP Richard R. Deluca sold 6,427 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the transaction, the executive vice president now directly owns 103,223 shares in the company, valued at approximately $8,783,245.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert M. Davis sold 216,718 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the transaction, the chief financial officer now owns 354,378 shares in the company, valued at $30,274,512.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

MRK has been the topic of several recent research reports. Argus lifted their target price on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Svb Leerink initiated coverage on Merck & Co., Inc. in a report on Friday, August 16th. They set an “outperform” rating and a $103.00 target price on the stock. UBS Group lifted their target price on Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Mizuho reaffirmed a “buy” rating and set a $97.00 target price on shares of Merck & Co., Inc. in a report on Monday, August 5th. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Merck & Co., Inc. has a consensus rating of “Buy” and an average target price of $92.56.

Shares of MRK traded down $1.10 on Friday, hitting $85.62. 475,403 shares of the stock traded hands, compared to its average volume of 9,420,273. The company has a market capitalization of $219.30 billion, a PE ratio of 19.72, a P/E/G ratio of 1.74 and a beta of 0.56. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21. The business has a 50 day simple moving average of $83.55 and a 200 day simple moving average of $81.17. Merck & Co., Inc. has a one year low of $66.10 and a one year high of $87.25.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.06 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 4.91 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 2.57%. The ex-dividend date is Friday, September 13th. Merck & Co., Inc.’s payout ratio is currently 50.69%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: Trade War

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.